UBS Group Reaffirms “Buy” Rating for CVS Health (NYSE:CVS)

CVS Health (NYSE:CVS)‘s stock had its “buy” rating reaffirmed by equities researchers at UBS Group in a research note issued on Thursday. They currently have a $78.00 price objective on the pharmacy operator’s stock. UBS Group’s target price points to a potential upside of 7.63% from the stock’s current price.

CVS has been the topic of a number of other research reports. Cowen set a $76.00 price objective on shares of CVS Health and gave the company a “buy” rating in a research report on Monday, October 21st. SunTrust Banks increased their price objective on shares of CVS Health to $85.00 and gave the company a “buy” rating in a research report on Thursday. Royal Bank of Canada assumed coverage on shares of CVS Health in a research report on Friday, September 27th. They set an “outperform” rating and a $85.00 price objective on the stock. ValuEngine upgraded shares of CVS Health from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 2nd. Finally, Raymond James increased their price target on shares of CVS Health from $75.00 to $80.00 and gave the stock a “strong-buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, seven have given a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $77.59.

CVS Health stock traded up $0.69 during midday trading on Thursday, reaching $72.47. 9,079,719 shares of the company traded hands, compared to its average volume of 6,966,567. The firm has a market capitalization of $87.55 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.86. The business has a 50 day moving average of $64.66 and a two-hundred day moving average of $58.54. CVS Health has a 12 month low of $51.72 and a 12 month high of $82.15. The company has a debt-to-equity ratio of 1.39, a current ratio of 0.95 and a quick ratio of 0.64.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.77 by $0.07. The company had revenue of $64.81 billion for the quarter, compared to the consensus estimate of $62.99 billion. CVS Health had a net margin of 1.91% and a return on equity of 16.15%. The firm’s revenue for the quarter was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.73 earnings per share. As a group, equities analysts forecast that CVS Health will post 6.99 EPS for the current year.

In other news, CFO Eva C. Boratto sold 8,130 shares of the firm’s stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $65.00, for a total transaction of $528,450.00. Following the sale, the chief financial officer now directly owns 55,273 shares in the company, valued at approximately $3,592,745. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joshua Matthew Flum sold 17,703 shares of the firm’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $63.00, for a total transaction of $1,115,289.00. Following the sale, the executive vice president now owns 36,163 shares in the company, valued at $2,278,269. The disclosure for this sale can be found here. Insiders have sold a total of 49,437 shares of company stock worth $3,248,811 over the last 90 days. Insiders own 0.53% of the company’s stock.

Several hedge funds have recently made changes to their positions in CVS. 1 North Wealth Services LLC purchased a new position in CVS Health during the third quarter valued at $29,000. Centaurus Financial Inc. grew its stake in CVS Health by 570.8% during the first quarter. Centaurus Financial Inc. now owns 1,630 shares of the pharmacy operator’s stock valued at $30,000 after acquiring an additional 1,387 shares in the last quarter. Manchester Financial Inc. purchased a new position in CVS Health during the second quarter valued at $31,000. Hudock Capital Group LLC grew its stake in CVS Health by 54.0% during the second quarter. Hudock Capital Group LLC now owns 576 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 202 shares in the last quarter. Finally, Executive Wealth Management LLC grew its stake in CVS Health by 62.4% during the second quarter. Executive Wealth Management LLC now owns 565 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 217 shares in the last quarter. Hedge funds and other institutional investors own 76.17% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Recommended Story: Day Trading

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.